Trading was light with 162K shares changing hands on Tuesday. Shares saw a steep decrease in trading volume of 84.74% under the normal average daily volume.
Investors are more bearish on shares of the company of late if you pay attention to the rise in short interest. The company had a rise in short interest between September 29, 2017 and October 13, 2017 of 0.26%. Short interest grew from 14,189,961 to 14,226,607 over that timeframe. Days to cover decreased from 11.0 to 7.0 and the percentage of shorted shares was 0.51% on October 13.
The following firms have recently changed their position in CYTR. Bank Of NEW York Mellon Corp augmented its position by buying 10,528 shares an increase of 117.8% from 06/30/2017 to 09/30/2017. Bank Of NEW York Mellon Corp currently owns 19,467 shares valued at $8,000. The total value of its holdings increased 33.3%. Citadel Advisors LLC trimmed its stake by shedding 14,200 shares a decrease of 41.2%. Citadel Advisors LLC controls 20,300 shares with a value of $8,000. The value of the position overall is down by 63.6%.
Citigroup Inc bolstered its ownership by buying 4,400 shares an increase of 17.0% in the quarter. Citigroup Inc claims 30,300 shares worth $12,000. The value of the position overall is down by 25.0%. Raymond James & Associates added to its holdings by buying 5,019 shares an increase of 9.6% as of 09/30/2017. Raymond James & Associates now holds 57,291 shares with a value of $23,000. The value of the position overall is down by 30.3%.
In the market the company is trading up by 2.68% since yesterday’s close of 1.86. The company currently has a P/E ratio of N/A and market cap is 52.78M. As of the latest earnings report the EPS was $-2.84 with 27.64M shares outstanding.
CytRx Corporation, launched on February 28, 1985, is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. The Company is involved in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. The Company is also involved in evaluating aldoxorubicin in a global Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus (HIV)-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. The Company has also completed a global Phase IIb clinical trial with aldoxorubicin as a first-line therapy for STS; a Phase Ib/II clinical trial primarily in the same indication; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors..